Skip to main content

Table 1 Demographic and clinical characteristics of patients with rheumatoid arthritis and psoriatic arthritis

From: Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells

  RA PsA
Age, years 65 [51–74] 56 [44–74]
Sex, male/female 15/114 24/29
DAS28-ESR 5.97 [4.99–6.71] 5.50 [4.05–6.78]
DAS28-ESR 2.6–5.1/DAS28-ESR >5.1, % 25.0%/75.0% 41.8%/58.2%
CDAI 37.0 [24.0–44.1] 33.6 [14.0–52.1]
Disease duration, years 18.5 [9.0–29.0] 14.0 [8.0–30.0]
ESR, mm/h 27.5 [19.0–39.5] 14.5 [4.0–46.5]
CRP, mg/L 11.9 [4.8–24.5] 2.7 [0.7–29.1]
RF, IU/L 79.7 [15.0–239.0] N/A
ACPA, EU/L 68.7 [2.2–270.8] N/A
Tender joint count (out of 28) 15 [8–22] 17 [3–26]
Swollen joint count (out of 28) 7 [2–12] 6 [0–14]
Disease activity, cm, physician’s VAS assessment 7.0 [5.5–8.8] 6.4 [4.7–9.0]
Disease activity, cm, patient’s VAS assessment 7.0 [5.0–8.8] 6.9 [4.9–8.2]
  1. Abbreviations: RA Rheumatoid arthritis, PsA Psoriatic arthritis, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, CDAI Clinical Disease Activity Index, DAS28-ESR Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, VAS Visual analogue scale, RF Rheumatoid factor, ACPA Anticitrullinated protein antibodies, EU  ELISA units, N/A Not applicable
  2. Values are presented as median with IQR, except DAS28 and sex categories